Patients with head and neck cancer cured by radiation therapy: A survey of the dry mouth syndrome in long-term survivors

Head and Neck

Volumn 24, Issue 8, 2002, Pages 737-747

  Wijers, Oda B ^a   Levendag, Peter C ^a   Braaksma, Mirjam M J ^a   Boonzaaijer, Meindert ^a   Visch, Leo L ^a   Schmitz, Paul I M ^a  

^a ERASMUS MEDICAL CENTER   (Netherlands)

Author keywords

Quality of life; Radiation therapy; Salivary glands; Xerostomia

Indexed keywords

ADULT; AGED; ARTICLE; CANCER RADIOTHERAPY; CLINICAL ARTICLE; EATING DISORDER; FEMALE; HEAD AND NECK CANCER; HUMAN; MALE; PRIORITY JOURNAL; RADIATION DOSE; SIMULATION; SPEECH DISORDER; VISUAL ANALOG SCALE; XEROSTOMIA; CHRONIC DISEASE; HEAD AND NECK TUMOR; MIDDLE AGED; MULTIVARIATE ANALYSIS; QUESTIONNAIRE; RADIATION EXPOSURE; RADIATION INJURY; RADIOTHERAPY; REGRESSION ANALYSIS; RETROSPECTIVE STUDY; SALIVARY GLAND; SURVIVOR;

ADULT; AGED; AGED, 80 AND OVER; CHRONIC DISEASE; FEMALE; HEAD AND NECK NEOPLASMS; HUMAN; MALE; MIDDLE AGE; MULTIVARIATE ANALYSIS; QUESTIONNAIRES; RADIATION INJURIES; RADIOTHERAPY; RADIOTHERAPY DOSAGE; REGRESSION ANALYSIS; RETROSPECTIVE STUDIES; SALIVARY GLANDS; SURVIVORS; XEROSTOMIA; HUMANS; MIDDLE AGED;

EID: 0036023212     PISSN: 10433074     EISSN: None     Source Type: Journal    
DOI: 10.1002/hed.10129     Document Type: Article

References (70)

1. Radiosensitivity of the human parotid gland
2. The function of the parotid gland following radiation therapy for head and neck cancer
3. Parotid gland function during and following radiotherapy of malignancies in the head and neck
4. Parotid gland function following accelerated and conventionally fractionated radiotherapy
5. Salivary flow rates in patients with head and neck cancer 0.5 to 25 years after radiotherapy
6. Late effects of radiation therapy in the head and neck region
7. A return to "normal eating" after curative treatment for oral cancer. What are the long-term prospects
8. How much saliva is enough? Normal function defined
9. Subjective reports of xerostomia and objective measures of salivary gland performance
10. Gingival health and salivary function in head and neck-irradiated patients
11. The dental problems of patients with head and neck cancer treated with CHART
12. Manifestations and treatment of xerostomia and associated oral effects secondary to head and neck radiation therapy
13. Mastication and swallowing in patients with postirradiation xerostomia
14. Influence of late side-effects upon daily life after radiotherapy for laryngeal and pharyngeal cancer
15. Quality of life in patients treated for head and neck cancer: A follow up study 7 to 11 years after radiotherapy
16. Patient self-reported and clinician-rated quality of life in head and neck cancer patients: A cross sectional study
17. Quality of Life and functional status measures in patients with head and neck cancer
18. Detailed quality of life assessment in patients treated with primary radiotherapy for squamous cell cancer of the base of the tongue
19. Head and neck cancer-specific quality of life. Instrument validation
20. Quality of life and oral function following radiotherapy for head and neck cancer
21. Effect of the application of a mucin-based saliva substitute on the oral microflora of xerostomic patients
22. Pathogenesis of radiation injury to the salivary glands and potential methods of protection
23. Pilocarpine treatment of salivary gland hypofunction and dry mouth (xerostomia)
24. Oral pilocarpine for radiation-induced xerostomia: Integrated efficacy and safety results from two prospective randomized clinical trials
25. Concomitant pilocarpine during head and neck irradiation is associated with decreased posttreatment xerostomia
26. Preservation of the rat parotid gland function after radiation by prophylactic pilocarpine treatment: Radiation dose dependency and compensatory mechanisms
27. Post-radiation severe xerostomia relieved by pilocarpine: A prospective French cooperative study
28. Protective effect of amifostine on dental health after radiotherapy of the head and neck
29. Phase III randomized trial of amifostine as a radioprotector in head and neck cancer
30. A double-blind crossover trial of CMC-and mucin-containing saliva substitutes
31. Comparison between new saliva stimulants in patients with dry mouth: A placebo-controlled double-blind cross-over study
32. A clinical comparative trial of saliva substitutes in radiation-induced salivary gland hypofunction
33. Acupuncture for pilocarpine-resistant xerostomia following radiotherapy for head and neck malignancies
34. A feasibility study of salivary gland autograft transplantation for xerostomia
35. Submandibular gland transfer prevents radiation-induced xerostomia
36. The potential for sparing of parotids and escalation of biologically effective dose with intensity-modulated radiation treatments of head and neck cancers: A treatment design study
37. Parotid gland sparing in patients undergoing bilateral head and neck irradiation: Techniques and early results
38. Ipsilateral parotid sparing study in head and neck cancer patients who receive radiation therapy. Results after 1 year
39. Parotid sparing study in head and neck cancer patients receiving bilateral radiation therapy: One-year results
40. Comprehensive irradiation of head and neck cancer using conformal multisegmental fields: Assessment of target coverage and noninvolved tissue sparing
41. Dose, volume and function relationships in parotid salivary glands following conformal and intensity-modulated irradiation of head and neck cancer
42. Beam intensity modulation using tissue compensators or dynamic multileaf collimation in three-dimensional conformal radiotherapy of primary cancers of the oropharynx and larynx, including the elective neck
43. A prospective study of salivary function sparing in patients with head-and-neck cancers receiving intensity-modulated or three dimensional radiation therapy: Initial results
44. Adjuvant and adjunctive chemotherapy in the management of squamous cell carcinoma of the head and neck region. A meta-analysis of prospective and randomized trials
45. Randomized clinical trial on 7-day-continuous accelerated irradiation (CAIR) of head and neck cancer-report on 3-year tumour control and normal tissue toxicity
46. Altered fractionation: Limited by mucosal reactions?
47. Assessing head and neck cancer patient outcome domains
48. Effect of amifostine on patient assessed clinical benefit in irradiated head and neck cancer
49. Late effects toxicity scoring: The SOMA scale
50. Toxicity in head and neck cancer: A review of trends and issues
51. Quantitative dose-volume response analysis of changes in the parotid function after radiotherapy in the head-and-neck region
52. Xerostomia and its predictors following parotid-sparing irradiation of head and neck cancer
53. Alterations in whole saliva flow rate induced by fractionated radiotherapy
54. Oral Pilocarpine for post-irradiation xerostomia in patients with head and neck cancer
55. Preliminary results of a pilot study using WR-2721 before fractionated irradiation of the head and neck to reduce salivary gland dysfunction
56. Oral side effects of head and neck irradiation: Correlation between clinical manifestations and laboratory data
57. Fractionated high dose rate brachytherapy in primary carcinoma of the nasopharynx
58. Fractionated high-dose-rate and pulsed-dose-rate brachytherapy: First clinical experience in squamous cell carcinoma of the tonsillar fossa and soft palate
59. Local tumor control in radiation therapy of cancers in the head and neck
60. Quality of life in patients cured from a carcinoma of the head and neck by radiotherapy: The importance of the target volume
61. Assessing quality of life in head and neck cancer
62. Variation in parotid gland size, configuration, and anatomic relations
63. CT-based parotid gland location: Implications for preservation of parotid function
64. Studies on human minor salivary gland secretions using the Periotron method
65. Evaluation of submandibular salivary flow rate in different age groups
66. Whole salivary flow rates following submandibular gland resection
67. The Head and Neck Radiotherapy Questionnaire: A morbidity/quality-of-life instrument for clinical trials of radiation therapy in locally advanced head and neck cancer
68. Quality of life in head and neck cancer patients: Validation of the European Organization for Research and Treatment of Cancer Questionnaire-H&N35
69. Assessing quality of life in patients treated for advanced head and neck cancer
70. Development of a head and neck companion module for the quality of life-radiation therapy instrument (QOL-RTI)